Dr. Adilson Kleber Ferreira is presently the principal investigator at Biomedical Science Institute of Department of Immunology. He accomplished his Ph.D. research in the area of developments of new anticancer drugs at the Faculty of Medicine of the University of Sao Paulo in Brazil. Ferreira also did your Ph.D. in Oncology at Frank`s Laboratory at the University of Groningen Netherlands, studying the molecular effects of new drugs candidate against non-small cell lung cancer. He also completed his training with a one-year post-doctoral fellowship in the University Medical Center Groningen, Netherlands - Research Institute for Drug Exploration of Department of Oncology. He also did postdoctoral research at Department of Immunology, and it was aimed at development and validation of new anticancer compound to lung cancer treatment. At the same time research in the field of oncology and immunology in cancer treatment was further extended, focusing on ration drug design as a tool to develop new anticancer compound or new strategy in the fighter against cancer. He has interest in developing new anticancer drugs base on ration drug discovery. His particular motivation is establishing an interactive and multidisciplinary cycle regarding the development and optimization of novel leads (new chemical entities), integrating the computer-aided drug design (CADD), organic chemistry and experimental evaluation research fields.

Anticancer Drug Discovery; New Target; Drug Screnning; Ration Drug Design; Immunoterapy.